Full Breakdown
U.S. Re-engages with Gavi Vaccine Alliance Amid Ebola Outbreak
6/3/2026, 6:34:00 AM
Background: Funding Cut, Thimerosal Issue, and Ebola Threat
In June 2026, Secretary of State Marco Rubio announced that the United States would resume engagement with Gavi, the global vaccine alliance, after Health Secretary Robert F. Kennedy Jr. halted roughly $300 million per year of U.S. contributions in 2025 over concerns about the mercury-based preservative thimerosal. Gavi, which holds a 500,000-dose stockpile for Zaire-ebolavirus, is now responding to a Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. Gavi has earmarked $50 million ($10 million immediate, $40 million to speed vaccine development) and the State Department has pledged over $162 million for the response.
Key Participants and Their Roles
Key participants include Secretary of State Marco Rubio, who is directing the re-engagement; Health Secretary Robert F. Kennedy Jr., whose safety concerns prompted the funding pause; Gavi CEO Sania Nishtar, who welcomed the prospect of releasing congressionally appropriated funds; an HHS spokesperson, who noted direct talks with Gavi; and Senators Jeanne Shaheen (D-NH) and Cory Booker (D-NJ), who have urged the release of the $600 million withheld for two years.
Official Statements & Policy Direction
Rubio told the Senate Foreign Relations Committee that the State Department had decided to re-engage with Gavi, respecting HHS’s views, and seeks an outcome acceptable to Congress and U.S. global-health goals. The HHS spokesperson said both agencies remain cautiously optimistic that discussions will yield greater transparency and accountability. Gavi’s CEO emphasized that unlocking the appropriated funds would keep the world safe from infectious-disease threats.
Criticism, Opposition, and Safety Debate
Anti-vaccine groups, including one founded by Kennedy, claim thimerosal causes autism, though multiple studies have found no safety link. Kennedy’s allegation that Gavi ignored safety lacks supporting evidence. Gavi’s board is transitioning to thimerosal-free vaccines, a step that satisfies the U.S. conditionality.
Conflicting Reports & Gaps
Sources confirm the U.S. withheld $600 million approved by Congress, but the timeline for release is unspecified. The degree to which Gavi’s board has formally committed to fully phase out thimerosal is not detailed. Likewise, the precise effect of the $162 million State Department pledge on outbreak containment has not been quantified.
Verbatim Quotes
- “we need to drive this to an outcome” — Marco Rubio, U.S. Secretary of State
- “Unlocking the funds that Congress has appropriated to Gavi would enable us to keep the world safe from infectious disease threats,” — Sania Nishtar, Gavi CEO
- “Rubio added: “I wouldn’t use the word defer, but we have certainly allowed him to play a leading role in determining what we’re going to do next.” — Marco Rubio
- “[We] remain cautiously optimistic that ongoing discussions can produce greater transparency, accountability, and a constructive path forward,” — HHS spokesperson
Outlook: Funding Release and Ongoing Negotiations
The State Department and HHS will keep direct talks with Gavi to finalize the $600 million release and to monitor the Bundibugyo response. Congressional oversight and Senate health-committee input are expected to shape the final funding agreement, while Gavi advances vaccine development for the emergent Ebola strain.
